Routine cholesterol surveillance in child- hood. Pediatrics. 1989;84:751 5. S4.4.4.3-22. Ned RM, Sijbrands EJ. Cascade screening for familial hypercholes- terolemia (FH) PLoS Curr. 2011;3:RRN1238. S4.4.4.3-23. Bender R, Bell DA, Hooper AJ, et al. Screening for familial hyper- cholesterolaemia. Pathology. 2012;44:122 8. S4.4.4.3-24. National Institute for Health and Care Excellence (NICE) (UK). Familial hypercholesterolaemia: identification and management. Available at: http://www.nice.org.uk/guidance/CG71. Accessed August 24, 2018. S4.4.4.3-25. Kit BK, Kuklina E, Carroll MD, et al. Prevalence of and trends in dyslipidemia and blood pressure among US children and adoles- cents, 1999 2012 JAMA Pediatr. 2015;169:272 9. S4.4.4.3-26. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular dis- ease risk factors among US adolescents, 1999 2008 Pediatrics. 2012;129:1035 41. S4.4.4.3-27. Lozano P, Henrikson NB, Morrison CC, et al. Lipid screening in childhood and adolescence for detection of multifactorial dys- lipidemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:634 44. S4.4.4.3-28. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167 92. S4.4.4.3-29. Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in child- hood and adolescence for detection of familial hypercholesterol- emia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:645 55. S4.4.4.3-30. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2017;7:CD006401. S4.4.4.3-31. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvas- tatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64:285 96. S4.4.4.3-32. Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis pro- gression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557 66. S4.4.4.3-33. 